John Calhoun, MD
Internal Medicine · Charleston, SCNPI 1770845141
Payments from drug & device makers
Across 226 payments — averaging $13.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$583
- AbbVie$520
- Novo Nordisk$300
- GSK$215
- Nevro Corp.$197
- Amarin Pharma, Inc.$149
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,984100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $583 |
| AbbVie(2 entities) | 34 | $520 |
| Novo Nordisk | 34 | $300 |
| GSK | 12 | $215 |
| Nevro Corp. | 9 | $197 |
| Amarin Pharma, Inc. | 8 | $149 |
| Novartis | 8 | $115 |
| Abiomed | 2 | $115 |
| Abbott | 8 | $110 |
| Amgen(2 entities) | 7 | $109 |
| AstraZeneca | 7 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Medtronic | 1 | $59 |
| Pfizer | 4 | $58 |
| Lilly USA, LLC | 3 | $45 |
| Dexcom, Inc. | 3 | $44 |
| Shire North American Group Inc | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$2,995 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 224 | $245,310 |
| EliquisApixaban | 176 | $157,684 |
| JanuviaSitagliptin Phosphate | 89 | $106,072 |
| OzempicSemaglutide | 84 | $94,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $78,500 |
| JardianceEmpagliflozin | 57 | $78,239 |
| XareltoRivaroxaban | 51 | $40,408 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $31,398 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $30,819 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $28,134 |
| LinzessLinaclotide | 30 | $25,149 |
| MyrbetriqMirabegron | 33 | $20,542 |
| TrulicityDulaglutide | 19 | $19,914 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $19,221 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $15,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $45 | $265,224243 claims |
| PfizerEliquis | $58 | $157,684176 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $215 | $119,673185 claims |
| Novo NordiskOzempic, Rybelsus | $300 | $109,11297 claims |
| Boehringer IngelheimJardiance | $12 | $78,23957 claims |
| Johnson & JohnsonXarelto | $583 | $40,40851 claims |
| AbbVieLinzess, Savella | $520 | $30,71343 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $20,54233 claims |
| AstraZenecaFarxiga | $97 | $13,65216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- James ThomasCharleston$154K
- John CleekCharleston$136K
- Shakaib RehmanCharleston$94K
- Leonard AlsfeldCharleston$91K
- Samuel Schumann IiiCharleston$48K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.